Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

73 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Gabapentin use in a managed medicaid population.
Hamer AM, Haxby DG, McFarland BH, Ketchum K. Hamer AM, et al. J Manag Care Pharm. 2002 Jul-Aug;8(4):266-71. doi: 10.18553/jmcp.2002.8.4.266. J Manag Care Pharm. 2002. PMID: 14613419
Rates of adverse events of long-acting opioids in a state Medicaid program.
Hartung DM, Middleton L, Haxby DG, Koder M, Ketchum KL, Chou R. Hartung DM, et al. Ann Pharmacother. 2007 Jun;41(6):921-8. doi: 10.1345/aph.1K066. Epub 2007 May 15. Ann Pharmacother. 2007. PMID: 17504834
An evaluation of Oregon's evidence-based Practitioner-Managed Prescription Drug Plan.
Hartung DM, Ketchum KL, Haxby DG. Hartung DM, et al. Health Aff (Millwood). 2006 Sep-Oct;25(5):1423-32. doi: 10.1377/hlthaff.25.5.1423. Health Aff (Millwood). 2006. PMID: 16966742
Initial results of the use of prescription order change forms to achieve dose form optimization (consolidation and tablet splitting) of SSRI antidepressants in a state Medicaid program.
Hamer AM, Hartung DM, Haxby DG, Ketchum KL, Pollack DA. Hamer AM, et al. J Manag Care Pharm. 2006 Jul-Aug;12(6):449-56. doi: 10.18553/jmcp.2006.12.6.449. J Manag Care Pharm. 2006. PMID: 16925452
Improving outpatient warfarin use for hospitalized patients with atrial fibrillation.
Touchette DR, Mcguinness ME, Stoner S, Shute D, Edwards JM, Ketchum K. Touchette DR, et al. Pharm Pract (Granada). 2008 Jan;6(1):43-50. doi: 10.4321/s1886-36552008000100007. Epub 2008 Mar 10. Pharm Pract (Granada). 2008. PMID: 25170363 Free PMC article.
Changes in long-acting β-agonist utilization after the FDA's 2010 drug safety communication.
Hartung DM, Middleton L, Markwardt S, Williamson K, Ketchum K. Hartung DM, et al. Clin Ther. 2015 Jan 1;37(1):114-123.e1. doi: 10.1016/j.clinthera.2014.10.025. Epub 2014 Nov 25. Clin Ther. 2015. PMID: 25465946
Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma.
Gillette MA, Satpathy S, Cao S, Dhanasekaran SM, Vasaikar SV, Krug K, Petralia F, Li Y, Liang WW, Reva B, Krek A, Ji J, Song X, Liu W, Hong R, Yao L, Blumenberg L, Savage SR, Wendl MC, Wen B, Li K, Tang LC, MacMullan MA, Avanessian SC, Kane MH, Newton CJ, Cornwell M, Kothadia RB, Ma W, Yoo S, Mannan R, Vats P, Kumar-Sinha C, Kawaler EA, Omelchenko T, Colaprico A, Geffen Y, Maruvka YE, da Veiga Leprevost F, Wiznerowicz M, Gümüş ZH, Veluswamy RR, Hostetter G, Heiman DI, Wyczalkowski MA, Hiltke T, Mesri M, Kinsinger CR, Boja ES, Omenn GS, Chinnaiyan AM, Rodriguez H, Li QK, Jewell SD, Thiagarajan M, Getz G, Zhang B, Fenyö D, Ruggles KV, Cieslik MP, Robles AI, Clauser KR, Govindan R, Wang P, Nesvizhskii AI, Ding L, Mani DR, Carr SA; Clinical Proteomic Tumor Analysis Consortium. Gillette MA, et al. Cell. 2020 Jul 9;182(1):200-225.e35. doi: 10.1016/j.cell.2020.06.013. Cell. 2020. PMID: 32649874 Free PMC article.
73 results
Jump to page
Feedback